This review summarizes current and pipeline drugs for the treatment of melanoma. Melanoma is a highly aggressive skin cancer with a rising incidence. Standard treatments include surgery, radiation, chemotherapy, targeted therapy, and immunotherapy. Surgery is effective for localized melanoma, while radiation and chemotherapy are used for more advanced cases. However, resistance and side effects limit their effectiveness. Targeted therapies, such as BRAF and MEK inhibitors, have shown promise in patients with specific mutations. Immunotherapies, including checkpoint inhibitors like PD-1 and CTLA-4 blockers, have significantly improved outcomes in advanced melanoma. Combination therapies, such as BRAF/MEK inhibitors, enhance progression-free survival. Adoptive cell transfer therapies, including TIL and CAR-T, are being explored. Oncolytic virus therapy, like T-VEC, is also under investigation. Emerging therapies include IL-2 and oncolytic viruses. Despite progress, challenges remain, including variability in immunotherapy responses and the need for personalized approaches. Future research focuses on identifying biomarkers, improving drug delivery, and combining therapies to enhance efficacy and patient outcomes.This review summarizes current and pipeline drugs for the treatment of melanoma. Melanoma is a highly aggressive skin cancer with a rising incidence. Standard treatments include surgery, radiation, chemotherapy, targeted therapy, and immunotherapy. Surgery is effective for localized melanoma, while radiation and chemotherapy are used for more advanced cases. However, resistance and side effects limit their effectiveness. Targeted therapies, such as BRAF and MEK inhibitors, have shown promise in patients with specific mutations. Immunotherapies, including checkpoint inhibitors like PD-1 and CTLA-4 blockers, have significantly improved outcomes in advanced melanoma. Combination therapies, such as BRAF/MEK inhibitors, enhance progression-free survival. Adoptive cell transfer therapies, including TIL and CAR-T, are being explored. Oncolytic virus therapy, like T-VEC, is also under investigation. Emerging therapies include IL-2 and oncolytic viruses. Despite progress, challenges remain, including variability in immunotherapy responses and the need for personalized approaches. Future research focuses on identifying biomarkers, improving drug delivery, and combining therapies to enhance efficacy and patient outcomes.